AN IMPROVED PROCESS FOR PREPARING AN OPTICALLY ACTIVE PROTON PUMP INHIBITOR

(57) Abstract: An improved process for the preparation of (S)-5-methoxy-2-[[4-(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl]-l//-benzimidazole of Formula I. (I) with high enantiomeric excess from racemic mixture.
AN IMPROVED PROCESS FOR PREPARING AN OPTICALLY ACTIVE
PROTON PUMP INHIBITOR

FIELD OF THE INVENTION

The present invention relates to an improved process for the preparation of (S)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole of Formula I,

\[
\begin{array}{c}
\text{H}_3\text{CO} \\
\text{H}_3\text{C} \\
\text{N} \\
\text{O} \\
\text{N} \\
\text{OCH}_3 \\
\end{array}
\]

with high enantiomeric excess from racemic mixture.

BACKGROUND OF THE INVENTION

(S)-5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole of Formula I, which is generically known as Esomeprazole, is a Proton Pump Inhibitor. Esomeprazole Magnesium is being marketed under the Trade name NEXIUM as Delayed Release Capsules. Esomeprazole Sodium is also being marketed under the Trade name NEXIUM IV as an Intravenous Injection.

Esomeprazole is used for inhibiting gastric acid secretion in mammals and man. In a more general sense, esomeprazole is used for the treatment of gastric acid-related diseases and gastrointestinal inflammatory diseases in mammals and man, such as gastric ulcer, duodenal ulcer, reflux esophagitis, and gastritis.

Several processes to prepare esomeprazole have been disclosed in the prior-art, some of which are summarized below:
US 5,693,818 discloses a process to prepare esomeprazole by separating a diastereomeric ester of omeprazole, having either R or S configuration and dissolving each of the separated diastereomers in an alkaline solution of above pH 7 so as to hydrolyze the acyloxyethylmethyl group from the separated diastereomers to give the optically pure enantiomers which are neutralized with a neutralizing agent which can be an acid or an ester and the pH being maintained at or above 7 throughout the process to yield esomeprazole.

US 5,948,789 discloses a process to prepare esomeprazole, by reacting prochiral sulphide with cumene hydroperoxide in the presence of diethyl tartrate, titanium isopropoxide and amine. A disadvantage of this method is that the strict control on reaction conditions and quantities of oxidizing agents has to be maintained to avoid over oxidation of desired sulfoxide to sulfone impurity. Moreover, these methods require expensive reagents like titanium isoproxide and diethyl tartarate.

CN 1223262 A discloses a process to prepare esomeprazole, by dissolving racemic omeprazole and (S)-(+-)[1,1'-Binaphthylene]-2,2'-diol (BINOL) in a molar ratio of 1:0.5-2 at a temperature of 60-130°C in a solvent system such as benzene, toluene, dimethylbenzene and trimethylbenzene or acetonitrile for 12-72 h. The inclusion complex of esomeprazole and BINOL is subjected to conventional chromatographic separation to obtain optically pure esomeprazole. The reaction is carried out for longer periods, which is commercially not desirable. The maximum enantiomeric excess achieved by the above process is very low, approximately 80%.

WO 2006/094904 A1 discloses a process to prepare esomeprazole, which comprises treating the racemic mixture of omeprazole with BINOL in a molar ratio of 1:0.5-3, in a mixture of an amine and organic solvent to yield inclusion complex. The inclusion complex was treated with a hydroxide of an alkaline metal in a mixture of water and toluene to give optically pure esomeprazole. However, this process has yielded an
inclusion complex of esomeprazole and BINOL with 95.7% of maximum enantiomeric-excess, which requires further purification to achieve 99.7% enantiomeric excess, but this accompanied a yield loss of about 38% of inclusion complex.

WO 2007/013743 A1 discloses a process to prepare esomeprazole, which comprises treating the racemic mixture with BINOL with molar ratio of 1:0.5-0.7, in a mixture of a weak base, water and alcoholic solvent to yield the inclusion complex. The inclusion complex was treated with a hydroxide of an alkaline metal in water to give optically pure esomeprazole. However, the process yielded an inclusion complex of esomeprazole and BINOL having enantiomeric excess 96.8%, which requires further purification to achieve 99.4% enantiomeric excess, but this accompanied a yield loss of about 12% of inclusion complex.

In view of the above, it is desired to have a commercially viable process to prepare esomeprazole with high enantiomeric excess.

We have now found that by treating omeprazole with aromatic or polyaromatic phenols and optionally substituted phenols in the presence of BINOL yields esomeprazole with enhanced enantiomeric excess of greater than 98% and with a good quality. Further, the invention does not require any purification of esomeprazole-BINOL inclusion complex and carried out further reactions to yield esomeprazole with higher enantiomeric excess.

**OBJECTIVE**

The objective of the present invention is to provide an improved process for preparing optically pure esomeprazole with good quality and purity.
In yet another objective of the present invention is to provide an improved process for preparing esomeprazole, which is simple, industrially applicable and economically viable.

5 SUMMARY OF THE INVENTION

The present invention relates to an improved process for preparing esomeprazole of Formula I,

\[
\text{H}_3\text{CO} \quad \text{CH}_3 \\
\text{H}_3\text{C} \quad \text{S} \quad \text{N} \\
\text{N} \quad \text{OCH}_3 \\
\text{H}_3\text{C} \quad \text{O} \\
\]

Formula I

which comprises:

10 a) treating omeprazole with BINOL and an aromatic or polyaromatic phenol; 
b) isolating the esomeprazole- BINOL inclusion complex; and 
c) converting the esomeprazole- BINOL inclusion complex in a solvent to give esomeprazole; and 
d) optionally converting esomeprazole into its salts and hydrates thereof.

15 DETAILED DESCRIPTION OF THE INVENTION

BINOL as used herein refers to S-(-)-1,1-binaphthol. The aromatic or polyaromatic phenol as used herein refers to phenol, substituted phenol, naphthol, substituted naphthol, wherein substitution on phenol or naphthol is selected from hydroxy, thio, halo, nitro, amino, alkylamino, arylamino, alkyl, cycloalkyl, amido, carboxylic, carboxyl, thioalkyl, thioaryl.

A mixture of BINOL and an aromatic or polyaromatic phenol is brought to a temperature of 0-120 °C. The mixture can be prepared in the presence or absence of a solvent. Omeprazole is added to this reaction mixture at 0-120 °C. Thereafter, the
reaction mixture is cooled to 20-30°C if the reaction mixture temperature is 35-120°C. If the temperature of the reaction mixture is between 0-15°C, then the reaction mixture is heated to 20-30°C. The reaction mixture is seeded with esomeprazole-BINOL inclusion complex at 20-30°C and stirred for approximately 3 h to crystallize the product. To this reaction mass an antisolvent is added and stirred for 1-15 h at 20-30°C for complete crystallization of esomeprazole-S(-)-binaphthol inclusion complex product.

A mixture of BINOL and aromatic or polyaromatic phenol is heated for 30 min at 50-75°C. The mixture is prepared in presence or absence of a solvent. Omeprazole is added to this reaction mixture at 40-50°C and stirred for 30 min. The reaction mixture is seeded with esomeprazole-S(-)-binaphthol inclusion complex and stirred for 2 h to crystallize the product. To this reaction mass an antisolvent is added and slurried for 1-15 h at 20-30°C for complete crystallization of esomeprazole-S(-)-binaphthol inclusion complex product.

A mixture of BINOL and aromatic or polyaromatic phenol is heated to a temperature of 50-75°C for 30 min. The mixture is prepared in the presence or absence of a solvent. Omeprazole is added to the reaction mixture at 40-50°C and stirred for 30 min. The reaction mixture is seeded with esomeprazole- BINOL inclusion complex and cooled to 20-30°C. Then the reaction mass is stirred for 2 h to crystallize the product. To this reaction mass an antisolvent is added and stirred for 1-15 h at 20-30°C for complete crystallization of esomeprazole-S(-)-binaphthol inclusion complex.

A mixture of BINOL and aromatic or polyaromatic phenol is treated at a temperature 20-30°C. The mixture is prepared in the presence or absence of a solvent. Omeprazole is added to the reaction mixture and seeding the reaction mixture with esomeprazole-BINOL inclusion complex. Then the reaction mixture is stirred for 2 h to crystallize the product. To this reaction mass an antisolvent is added and stirred for 1-15 h at 20-30°C for complete crystallization of esomeprazole-S(-)-binaphthol inclusion complex.
A mixture of BINOL and aromatic or polyaromatic phenol is treated at a temperature 50-75°C for 30 min. The mixture is prepared in presence or absence of a solvent. Omeprazole is added to the reaction mixture at 40-50°C and stirred for 10 min. The reaction mixture is seeding with esomeprazole-BINOL inclusion complex. Thereafter, reaction mixture is cooled to 20-30°C and stirred for 2 h to crystallize the product. To this reaction mass an antisolvent is added and stirred for 1-15 h at 20-30°C for complete crystallization of esomeprazole-S-(−)-binaphthol inclusion complex product as a white solid.

The solvent as used herein is selected from the group consisting of aprotic solvent, such as esters, ethers, ketones, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols, water and mixtures thereof.

The antisolvent as used herein is selected from the group consisting of aprotic solvent, such as esters, ketones, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar solvents, such as alcohols, water and mixtures thereof.

The esters such as ethyl acetate, n-butyl acetate; ethers such as methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; ketones such as acetone, 2-butanone, and 4-methylpentan-2-one; nitriles such as acetonitrile; hydrocarbons such as benzene, toluene, heptane, hexane; chlorinated hydrocarbons such as carbon tetrachloride, methylene dichloride, chloroform; alcohols such as methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.

The major advantage realized with the process of the present invention is isolation of esomeprazole-BINOL inclusion complex as a white solid in good enantiomeric excess, whereas the prior-art processes produce a colored esomeprazole-BINOL inclusion
complex, and with lower enantiomeric excess. The esomeprazole salt obtained through white esomeprazole-BINOL inclusion complex has high purity and greater enantiomeric excess; greater than 99.9%.

The esomeprazole-BINOL inclusion complex is dissolved in a solvent and in the presence of organic and inorganic base selected from ammonia, triethyl amine, diisopropylethyl amine, sodium bicarbonate, sodium hydroxide, potassium hydroxide; alkali and alkaline earth metal selected from sodium methoxide, lithium methoxide, sodium ethoxide, lithium ethoxide, sodium metal; acid salts selected from sodium acetate, lithium acetate, potassium acetate. The aqueous layer is separated from the organic layer and thoroughly washed with a solvent. The aqueous layer is mixed with a solvent and pH of the reaction mixture is adjusted using an acid to yield esomeprazole. Acid is selected from hydrochloric acid, acetic acid, sulphuric acid; solvent is selected from aprotic solvent, such as esters, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols, water and mixtures thereof.

The esters are selected from ethyl acetate, n-butyl acetate; ethers are selected from methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; nitriles are selected from acetonitrile; hydrocarbons are selected from benzene, toluene, heptane, hexane; chlorinated hydrocarbons are selected from carbon tetrachloride, methylene dichloride, chloroform; alcohols are selected from methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.

The esomeprazole-BINOL inclusion complex is dissolved in a solvent and in the presence of organic and inorganic base selected from ammonia, triethyl amine, diisopropylethyl amine, sodium bicarbonate, sodium hydroxide, potassium hydroxide; alkali and alkaline earth metal selected from sodium methoxide, lithium methoxide, sodium ethoxide, lithium ethoxide, sodium metal; acid salts selected from sodium.
acetate, lithium acetate, potassium acetate. The aqueous layer is separated from the organic layer and thoroughly washed with a solvent. Thereafter, to the aqueous layer 20% w/w aqueous ammonium formate solution is added and extracted with a solvent. Solvent is selected from aprotic solvent, such as esters, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols; water and mixtures thereof. The layers were separated and the organic layer is washed with water and concentrated under reduced pressure to yield a foamy mass. The concentrated mass was dissolved in ethyl acetate and cooled to < 50°C. To the solution alkali and alkaline earth metal selected from sodium methoxide, lithium methoxide, sodium ethoxide, lithium ethoxide, sodium metal is added and stirred at 20-30°C for 90 min to 120 min to yield esomeprazole sodium. This is further converted to esomeprazole magnesium.

The BINOL used in the process is recovered from the extractions and can be recycled for further use.

The chiral purity of esomeprazole obtained by the process of the present is found out by using a Silica gel AGP column for chiral chromatography (100 x 4.0 mm) 5 µ and a mobile phase —Acetonitrile R, phosphate buffer solution pH 6 (65:435 v/v); flow rate 0.6 ml/min and is detected at 302 nm.

The esomeprazole, which is prepared by the above process, can be further converted into its pharmaceutically acceptable salts and hydrates thereof.

The esomeprazole magnesitum prepared by the process of the present invention can be anhydrate or hydrate, specifically trihydrate. The product can amorphous or crystalline or partially crystalline in nature.
The esomeprazole is effective as a gastric acid secretion inhibitor, and is useful as an antiulcer agent. Any suitable route of administration may be employed for providing the patient with an effective dosage of the esomeprazole. For example, oral, parenteral, subcutaneous, intramuscular, rectal, transdermal and the like may be employed. Dosage forms include capsules, tablets, dispersions, suspensions, solutions and the like.

The pharmaceutical compositions of the present invention comprise the esomeprazole as active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salt" refers to both acid and alkaline pharmaceutically acceptable non-toxic salts. Compositions comprising other therapeutic ingredients are especially of interest in the treatment of Helicobacter infections. The compositions include compositions suitable for oral, rectal or parenteral such as subcutaneous, intramuscular, and intravenous administration. The most preferred route of the present invention is the oral route. The compositions may be conveniently presented in unit dosage forms, and prepared by any methods well known in the art of pharmacy. The most suitable route of administration as well as the magnitude of a therapeutic dose of the esomeprazole or a pharmaceutically acceptable salt thereof in any given case will depend on the nature and severity of the disease to be treated.

The invention is illustrated with the following examples, which are provided by way of illustration only and should not be construed to limit the scope of the invention.

**EXAMPLE 1**

**PREPARATION OF ESOMEPRAZOLE-BINOL INCLUSION COMPLEX**

BINOL (6.63 g; 23.16 mmol) and phenol (4.09 g; 43.46 mmol) were added to toluene (70 ml) and heated the mixture to 75°C to obtain clear solution. Omeprazole (10 g; 28.95 mmol) was added to the reaction mass at 45°C and stirred for 10 min at 40-45°C. Thereafter, the reaction mass was seeded with esomeprazole-BINOL inclusion
complex. The reaction mass was cooled and stirred for 2h at 20-30°C to crystallize the product. Hexane (35 ml) was added to the reaction mass and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered and washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

Yield - 7.5 g (82 %)
Enantiomeric excess - 98.24 %.

EXAMPLE 2

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX
BINOL (6.22 g; 21.72 mmol) and phenol (4.09 g; 43.46 mmol) were added to toluene (70 ml) at 20-30°C. Omeprazole (10 g; 28.95 mmol) was added to the reaction mixture and seeded with esomeprazole-BINOL inclusion complex. Thereafter, the reaction mass was stirred for 2h to crystallize the product. Then, hexane (35 ml) was added to the reaction mass and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

Yield - 7.98 g (87.3 %)
Enantiomeric excess - 98.3 %.

EXAMPLE 3

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX
BINOL (31.08 g; 108.54 mmol) and phenol (20.4 g; 216.76 mmol) were added to toluene (350 ml) at 20-30°C. Omeprazole (50 g; 144.75 mmol) was added to the reaction mixture and seeded with esomeprazole-BINOL inclusion complex. The resulting reaction mixture was stirred for 3h to crystallize the product. Heptane (210 ml) was added to the reaction mass and stirred for 3h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-heptane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.
Yield - 37.7 g (82.45 %)
Enantiomeric excess - 98 %.

EXAMPLE 4

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX

BINOL (1.95 g; 6.81 mmol) and 2-naphthol (3.13 g; 21.71 mmol) were added to toluene (100 ml) and heated the mixture to 60°C to obtain clear solution. Omeprazole (5 g; 14.47 mmol) was added to the solution at 55°C and stirred for 10 min at 50-55°C. The reaction mixture was seeded with esomeprazole-BINOL inclusion complex and thereafter cooled and stirred for 2 h at 20-30°C to crystallize the product. Hexane (50 ml) was added to the reaction mass and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

Yield - 3.05 g (66.7 %)
Enantiomeric excess - 98.44 %.

EXAMPLE 5

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX

BINOL (2.5 g; 8.73 mmol) and 2-naphthol (2.61 g; 18.103 mmol) were added to toluene (100 ml) and heated the mixture to 60°C to obtain clear solution. Omeprazole (5 g; 14.47 mmol) was added to the solution at 55°C and stirred for 10 min at 50-55°C. The reaction mixture was seeded with esomeprazole-BINOL inclusion complex and thereafter cooled and stirred for 2 h at 20-30°C to crystallize the product. Hexane (50 ml) was added to the reaction mass and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

Yield - 3.65 g (79.86 %)
Enantiomeric excess - 98.16%.
EXAMPLE 6
PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX
BINOL (5 g; 17.462 mmol) and 2-naphthol (6.26 g; 43.42 mmol) were added to toluene
(200 ml) and heated the mixture to 60°C to obtain a clear solution. Omeprazole (10 g;
28.95 mmol) was added to the solution at 55°C and stirred for 10 min at 50-55°C. The
reaction mixture was seeded with esomeprazole-BINOL inclusion complex and thereafter cooled and stirred for 2 h at 20-30°C to crystallize the product. Hexane (100 ml) was added to the reaction mass and stirred for 6 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.
Yield - 6.4 g (69.7 %)
Enantiomeric excess - 98.28 %.

EXAMPLE 7
PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX
BINOL (1.66 g; 5.79 mmol) and phenol (0.27 g; 2.86 mmol) were added to toluene (30 ml) at 20-30°C and heated the mixture to 55°C. Omeprazole (2 g; 5.79 mmol) was added to the mixture and stirred at 50-55°C for 30 min. The solution was cooled to 30°C and seeded with esomeprazole-BINOL inclusion complex. The reaction mixture was stirred for 2 h to crystallize the product. To this mass, hexane (15 ml) was added and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture, and dried to obtain a white solid of esomeprazole-BINOL inclusion complex.

EXAMPLE 8
PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX
BINOL (4.14 g; 14.47 mmol) and phenol (1.36 g; 14.47 mmol) were added to toluene
(100 ml) at 20-30°C and heated the mixture to 45°C. Omeprazole (5 g; 14.47 mmol) was added to the mixture and stirred at 40-45°C for 30 min. The solution was cooled to 20-
30°C and stirred for 2 h to crystallize the product. Hexane (50 ml) was added to the reaction mass and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of inclusion complex of esomeprazole-BINOL.

EXAMPLE 9

PREPARATION OF ESOMEPROZOLE-BINOL INCLUSION COMPLEX

BINOL (1 g; 3.49 mmol) and phenol (0.545 g; 5.79 mmol) were added to the mixture of ethanol (16 ml) and water (4 ml) at 20-30°C and heated the mixture to 45°C. Omeprazole (2 g; 5.79 mmol) was added to the mixture and stirred at 40-45°C to obtain a clear solution. The solution was cooled to 30°C and seeded with esomeprazole-BINOL inclusion complex. The mixture was stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with mixture of water-ethanol (1:1) and dried to obtain off-white solid of esomeprazole-BINOL inclusion complex.

EXAMPLE 10

PREPARATION OF ESOMEPROZOLE- BINOL INCLUSION COMPLEX

BINOL (1.95 g; 6.81 mmol) and phenol (2.04 g; 21.68 mmol) were added to toluene (100 ml) and heated the mixture to 60°C to obtain clear solution. Omeprazole (5 g; 14.47 mmol) was added to the solution at 55°C. The reaction mixture was stirred at 50-55°C for 10 min and seeded with esomeprazole-BINOL inclusion complex. Further, the reaction mixture was stirred for 2 h at 20-30°C to crystallize the product. To this reaction mass hexane (50 ml) was added and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.
EXAMPLE 11

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX

BINOL (5 g; 17.462 mmol) and phenol (4.08 g; 43.35 mmol) were added to toluene (200 ml) and heated the mixture to 60°C to obtain clear solution. Omeprazole (10 g; 28.95 mmol) was added to the solution at 55°C and stirred for 10 min at 50-55°C. Thereafter, the reaction mass was seeded with esomeprazole- BINOL inclusion complex. The reaction mass was cooled and stirred for 2 h at 20-30°C to crystallize the product. To this reaction mass hexane (100 ml) was added and stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-hexane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

EXAMPLE 12

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX

BINOL (6.22 g; 21.72 mmol) and phenol (4.09 g; 43.46 mmol) were added to toluene (70 ml) at 20-30°C. Omeprazole (10 g; 28.95 mmol) was added to the reaction mixture and seeded with esomeprazole-BINOL inclusion complex. The reaction mixture was stirred for 3 h to crystallize the product. To this reaction mass heptane (52.5 ml) was added and stirred for 3 h at 20-30°C for complete crystallization of title compound, which was filtered, washed with toluene-heptane mixture and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

EXAMPLE 13

PREPARATION OF ESOMEPRAZOLE- BINOL INCLUSION COMPLEX

BINOL (15.54 g; 54.27 mmol) and omeprazole (25 g; 72.38 mmol) were added to phenol (20.44 g) at 20-30°C. Thereafter, the reaction mixture was seeded with esomeprazole-BINOL inclusion complex and stirred for 3 h to crystallize the product. To this reaction mass a mixture of hexane and toluene (0.6:1 v/v; 280 ml) was added and
stirred for 15 h at 20-30°C for complete crystallization of title compound, which was filtered and washed with hexane-toluene mixture (0.6: 1; 20 ml) and dried to obtain white solid of esomeprazole-BINOL inclusion complex.

5 EXAMPLE 14

PREPARATION OF ESOMEPRAZOLE

Esomeprazole-BINOL inclusion complex (100 g; 158.29 mmol; ee of 98.28%) was suspended in methyl ^-butyl ether (1300 ml). Aqueous sodium hydroxide solution (2.2 % w/w; 302 g) was added to the suspended mass at 20-30°C and stirred till clear solution was obtained. Thereafter, organic layer was separated and the aqueous layer was extracted with methyl t-butyl ether for recovery of BINOL. The organic layers were combined, concentrated and recovered 44.4 g of BINOL. To the aqueous layer, methylene chloride (300 ml) was added and pH was adjusted to 7-8 with 10 % v/v aqueous acetic acid. The organic layer was separated and washed with DM water and concentrated under reduced pressure to yield esomeprazole as a foamy solid mass. Yield - 54.5 g
Enantiomeric excess - 98.1 %.

20 EXAMPLE 15

PREPARATION OF ESOMEPRAZOLE SODIUM

Esomeprazole obtained in example 14 (54.5 g; 157.78 mmol), was dissolved in a solution of aqueous NaOH (136.24 g; 4.88 % w/w) and DM water (30 ml). The solution was washed with methylene chloride twice (200 ml x 2). The aqueous layer was filtered and concentrated completely under reduced pressure to yield viscous mass. Ethanol was added to the viscous mass and concentrated under reduced pressure. Thereafter, ethyl acetate was added and concentrated to dryness under reduced pressure to yield solid mass. Further, ethyl acetate (400 ml) was added and stirred the mixture under reflux for 30 min. Cooled the reaction mass to 20-30°C and stirred for 3 h. The separated solid was
filtered, washed with ethyl acetate and dried under reduced pressure at 40°C to yield esomeperazole sodium.

Yield - 50.6 g (87 %)

Enantiomeric excess - 99.96 %.

EXAMPLE 16

PREPARATION OF ESOMEPRAZOLE SODIUM

Esomeprazole-BINOL inclusion complex (100 g; 158.3 mmol; ee of 98.2%) was suspended in a mixture of methyl t-butyl ether (1300 ml) and DM water (400 ml). Aqueous sodium hydroxide solution (5 % w/w; 133 g) was added to the suspended mass at 20-30°C and stirred till clear solution was obtained. Thereafter, organic layer was separated and the aqueous layer was washed with methyl t-butyl ether. Thereafter, 20% aqueous ammonium formate solution (60ml) was added and extracted with methylene chloride (300ml). The organic layer was washed with DM water and concentrated under reduced pressure to yield a foamy mass. The concentrated mass was dissolved in ethylacetate (400 ml) and cooled to 0-5°C. To the solution, sodium ethoxide (10.77 g, mmol) was added and stirred at 20-30°C for 90 min. The separated solid mass was filtered, washed with ethyl acetate and dried under reduced pressure at 40°C to yield esomeprazole sodium.

Yield - 50.6 g

Enantiomeric excess - 99.96 %.

EXAMPLE 17

PREPARATION OF ESOMEPRAZOLE MAGNESIUM

Esomeprazole sodium (5 g; 13.61 mmol; e.e. of 99.98 %), was dissolved in DM water (63 ml) and filtered. To the filtrate, anhydrous MgCl₂ (0.648 g; 6.8 mmol) dissolved in DM water (25 ml) was added drop wise and stirred for 1h. The precipitated product was filtered, washed with DM water and dried under reduced pressure at 40°C to yield of amorphous esomeperazole magnesium trihydrate.
Yield - 4.4 g (85 %)
Enantiomeric excess - 100 %

**COMPARATIVE EXAMPLE**

**PREPARATION OF ESOMEPRAZOLE BINOL INCLUSION COMPLEX**

Omeprazole (60 mg; 0.174 mmol) and optical pure BINOL (50 mg; 0.174 mmol) were suspended in toluene (2 ml) and stirred for 36 h at room temperature to yield a solid of 26 mg (47.3 %) of the blue inclusion complex of esomeprazole-BINOL.

Enantiomeric excess - 11.3 %
WE CLAIM

1) An improved process for preparing esomeprazole of Formula I,

\[
\begin{array}{c}
\text{H}_2\text{CO} \\
\text{H}_3\text{C} \\
\text{CH}_3
\end{array}
\begin{array}{c}
\text{S} \\
\text{N} \\
\text{OCH}_3
\end{array}
\begin{array}{c}
\text{N} \\
\text{H}
\end{array}
\begin{array}{c}
\text{OCH}_3
\end{array}
\begin{array}{c}
\text{N}
\end{array}
\begin{array}{c}
\text{O}
\end{array}
\begin{array}{c}
\text{CH}_3
\end{array}
\]

Formula I

which comprises:

a) treating BINOL, omeprazole and an aromatic or polyaromatic phenols;
b) isolating the esomeprazole-BINOL inclusion complex; and
c) converting the esomeprazole-BINOL inclusion complex in a solvent to give esomeprazole; and
d) optionally converting esomeprazole into its salts and hydrates thereof.

2) The process according to claim 1, the aromatic or polyaromatic phenol such as phenol, substituted phenol, naphthol, substituted naphthol.

3) The process according to claim 2, wherein substitution on phenol or naphthol is selected from hydroxy, thio, halo, nitro, amino, alkylamino, alylamino, alkyl, cycloalkyl, amido, carboxylic, carboxyl, thioalkyl, thioaryl.

4) The process according to claim 1, wherein step (a) is carried out in the presence or absence of a solvent.

5) The process according to claim 4, wherein the solvent is selected from the group consisting of aprotic solvent, such as esters, ketones, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols, water and mixtures thereof.

6) The process according to claim 5, the esters are selected from ethyl acetate, n-butyl acetate; ethers are selected from methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; ketones are selected from acetone, 2-butanone,
and 4-methylpentan-2-one; nitriles are selected from acetonitrile; hydrocarbons are selected from benzene, toluene, heptane, hexane; chlorinated hydrocarbons are selected from carbon tetrachloride, methylene dichloride, chloroform; alcohols are selected from methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.

7) The process according to claim 6, wherein the solvent is toluene.

8) The process according to claim 1, wherein step (c) is carried out in the presence of organic and inorganic base selected from ammonia, triethyl amine, diisopropylethyl amine, sodium bicarbonate, sodium hydroxide, potassium hydroxide; alkali and alkaline earth metal selected from sodium methoxide, lithium methoxide, sodium ethoxide, lithium ethoxide, sodium metal; acid salts selected from sodium acetate, lithium acetate, potassium acetate.

9) The process according to claim 1, wherein the solvent in step (c) is selected from the group consisting of aprotic solvent, such as esters, ketones, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols, water and mixtures thereof.

10) The process according to claim 9, the esters are selected from ethyl acetate, n-butyl acetate; ethers are selected from methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; ketones are selected from acetone, 2-butanone, and 4-methylpentan-2-one; nitriles are selected from acetonitrile; hydrocarbons are selected from benzene, toluene, heptane, hexane; chlorinated hydrocarbons are selected from carbon tetrachloride, methylene dichloride, chloroform; alcohols are selected from methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.
11) An improved process for preparing esomeprazole of Formula I, which comprises:

a) treating BINOL and an aromatic or polyaromatic phenol in the presence or absence of a solvent at 0-120°C;

b) adding omeprazole into the reaction mixture at 0-120°C;

c) optionally cooling the reaction mixture to 20-30°C, if the reaction mixture temperature is 35-120°C;

d) optionally heating the reaction mixture to 20-30°C, if the reaction mixture temperature is 0-15°C;

e) seeding with esomeprazole-BINOL inclusion complex;

f) adding an antisolvent to the reaction mass at 20-25°C;

g) stirring the reaction mass for 1-15 h;

h) isolating the esomeprazole-BINOL inclusion complex; and

i) treating the esomeprazole-BINOL inclusion complex in a solvent to give esomeprazole; and

j) optionally converting esomeprazole into its salts and hydrates thereof.

12) An improved process for preparing esomeprazole of Formula I, which comprises:

a) treating BINOL and an aromatic or polyaromatic phenol in the presence or absence of a solvent at 50-75°C;

b) adding omeprazole into the reaction mixture at 40-50°C;

c) optionally seeding with esomeprazole-BINOL inclusion complex;
d) cooling the reaction mixture to 20-30°C; 

e) adding an antisolvent to the reaction mass at 20-30°C;  

f) stirring the reaction mass for 1-15 h;  

g) isolating the esomeprazole-BINOL inclusion complex; and  

h) treating the esomeprazole-BINOL inclusion complex in a solvent to give esomeprazole; and  

i) optionally converting esomeprazole into its salts and hydrates thereof.

13) An improved process for preparing esomeprazole of Formula I, 

\[
\text{H}_3\text{CO}\text{CH}_3
\]

\[
\text{CH}_3
\]

\[
\text{N} \quad \text{OCH}_3
\]

\[
\text{H}_3\text{C}
\]

\[
\text{S} \quad \text{N}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]

\[
\text{H}
\]

\[
\text{O}
\]
14) An improved process for preparing esomeprazole of Formula I,

\[
\begin{align*}
\text{H}_3\text{CO} & \quad \text{CH}_3 \\
\text{H}_3\text{C} & \quad \text{N} \\
\text{O} & \quad \text{H} \\
\text{S} & \quad \text{N} \\
\text{OCH}_3 & \quad \text{OCH}_3
\end{align*}
\]

which comprises:

a) treating BINOL and an aromatic or polyaromatic phenol in presence or absence of a solvent at 20-30°C;

b) adding omeprazole in to the reaction mixture at 20-30°C;

c) optionally seeding with esomeprazole-BINOL inclusion complex;

d) adding an antisolvent to the reaction mass at 20-25°C;

e) stirring the reaction mass for 1-15 h;

f) isolating the esomeprazole-BINOL inclusion complex; and

g) treating the esomeprazole-BINOL inclusion complex in a solvent to give esomeprazole; and

h) optionally converting esomeprazole into its salts and hydrates thereof.

15) The process according to claims 11, 12, 13 and 14, wherein the solvent in step (a) is selected from the group consisting of aprotic solvent, such as esters, ketones, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols, water and mixtures thereof.

16) The process according to claim 15, wherein the esters are selected from ethyl acetate, n-butyl acetate; ethers are selected from methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; ketones are selected from acetone, 2-butanoine, and 4-methylpentan-2-one; nitriles are selected from acetonitrile; hydrocarbons are selected from benzene, toluene, heptane, hexane; chlorinated hydrocarbons are selected from carbon tetrachloride, methylene
dichloride, chloroform; alcohols are selected from methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.

17) The process according to claim 16, wherein the solvent is toluene.

18) The process according to claims 11, 12, 13 and 14, wherein the antisolvent is selected from the group consisting of aprotic solvent, such as esters, ketones, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar solvents, such as alcohols, water and mixtures thereof.

19) The process according to claim 18, wherein the esters are selected from ethyl acetate, n-butyl acetate; ethers are selected from methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; ketones are selected from acetone, 2-butanone, and 4-methylpentan-2-one; nitriles are selected from acetonitrile; hydrocarbons are selected from benzene, toluene, heptane, hexane; chlorinated hydrocarbons are selected from carbon tetrachloride, methylene dichloride, chloroform; alcohols are selected from methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.

20) The process according to claims 11, 12, 13 and 14, wherein steps (g), (h) and (i) are carried out in the presence of organic and inorganic base selected from ammonia, triethyl amine, diisopropylethyl amine, sodium bicarbonate, sodium hydroxide, potassium hydroxide; alkali and alkaline earth metal selected from sodium methoxide, lithium methoxide, sodium ethoxide, lithium ethoxide, sodium metal; acid salts selected from sodium acetate, lithium acetate, potassium acetate.

21) The process according to claims 11, 12, 13 and 14, wherein the solvent in steps (g), (h) and (i) is selected from is selected from the group consisting of aprotic solvent, such as esters, ketones, ethers, nitriles, hydrocarbons, chlorinated hydrocarbons; polar aprotic solvents, such as dimethylformamide, dimethylsulfoxide; polar solvents, such as alcohols, water and mixtures thereof.
22) The process according to claim 21, wherein the esters are selected from ethyl acetate, n-butyl acetate; ethers are selected from methyl t-butyl ether, diethylether, dimethylether, diisopropylether, tetrahydrofuran; ketones are selected from acetone, 2-butanone, and 4-methylpentan-2-one; nitriles are selected from acetonitrile; hydrocarbons are selected from benzene, toluene, heptane, hexane; chlorinated hydrocarbons are selected from carbon tetrachloride, methylene dichloride, chloroform; alcohols are selected from methanol, ethanol, propanol, butanol, isopropyl alcohol, 1-propanol.

23) The process according to claims 1, 11, 12, 13 and 14, the esomeprazole is isolated in the form of a salt and hydrates thereof.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D401/12 A61K31/4439

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Inter πai, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2007/013743 A (HANMI PHARM IND CO LTD [KR]; HA TAE HEE [KR]; KIM WON JEONG [KR]; OH H) 1 February 2007 (20.07-02-01) cited in the application Example 2 (preparation of inclusion complex) and example 15 (purification thereof); examples 1-21</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>DENG J ET AL: &quot;Resolution of omeprazole by inclusion complexation with a chiral host BINOL&quot; TETRAHEDRON ASYMMETRY, PERGAMON, OXFORD; GB, vol. 11, no. 8, 1 May 200.0 (2000-05-01), pages 1729-1732, XP004204576 ISSN: 0957-4166 the whole document</td>
<td>1-23</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:
  'A' document defining the general state of the art which is not considered to be of particular relevance
  'E' earlier document but published on or after the international filing date
  'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  'O' document referring to an oral disclosure, use, exhibition or other means
  'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
'

Date of the actual completion of the international search
6 November 2008

Date of mailing of the international search report
14/11/2008

Name and mailing address of the ISA:
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040
Fax: (+31-70) 340-3016

Authorized officer
Goss, Ilaria
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent document</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>WO 2007013743 A</td>
<td>01-02-2007</td>
<td>AU 2006273050 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2616119 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101208330 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008194828 A1</td>
</tr>
<tr>
<td>WO 2006094904 A</td>
<td>14-09-2006</td>
<td>AT 406362 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2006222032 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2598224 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101133049 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2259269 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2008531641 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20070113212 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008167473 A1</td>
</tr>
</tbody>
</table>